Literature DB >> 12720255

Missing... presumed at random: cost-analysis of incomplete data.

Andrew Briggs1, Taane Clark, Jane Wolstenholme, Philip Clarke.   

Abstract

When collecting patient-level resource use data for statistical analysis, for some patients and in some categories of resource use, the required count will not be observed. Although this problem must arise in most reported economic evaluations containing patient-level data, it is rare for authors to detail how the problem was overcome. Statistical packages may default to handling missing data through a so-called 'complete case analysis', while some recent cost-analyses have appeared to favour an 'available case' approach. Both of these methods are problematic: complete case analysis is inefficient and is likely to be biased; available case analysis, by employing different numbers of observations for each resource use item, generates severe problems for standard statistical inference. Instead we explore imputation methods for generating 'replacement' values for missing data that will permit complete case analysis using the whole data set and we illustrate these methods using two data sets that had incomplete resource use information. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12720255     DOI: 10.1002/hec.766

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  100 in total

1.  Estimates of patient costs related with population morbidity: can indirect costs affect the results?

Authors:  M Carreras; M García-Goñi; P Ibern; J Coderch; L Vall-Llosera; J M Inoriza
Journal:  Eur J Health Econ       Date:  2010-03-20

2.  Guidelines for conducting and reporting economic evaluation of fall prevention strategies.

Authors:  J C Davis; M C Robertson; T Comans; P A Scuffham
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

3.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

Review 4.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 5.  Good practice guidelines for the use of statistical regression models in economic evaluations.

Authors:  Ben Kearns; Roberta Ara; Allan Wailoo; Andrea Manca; Monica Hernández Alava; Keith Abrams; Mike Campbell
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

6.  Estimating 'costs' for cost-effectiveness analysis.

Authors:  Alec Miners
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  The impact of missing data in the estimation of concentration index: a potential source of bias.

Authors:  Hai Zhong
Journal:  Eur J Health Econ       Date:  2009-07-15

Review 8.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

9.  Cost-effectiveness of individual versus group female-specific cognitive behavioral therapy for alcohol use disorder.

Authors:  Todd A Olmstead; Fiona S Graff; Alyssa Ames-Sikora; Barbara S McCrady; Ayorkor Gaba; Elizabeth E Epstein
Journal:  J Subst Abuse Treat       Date:  2019-02-07

10.  Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Renatus Ziegler; Gunver S Kienle; Stefan N Willich; Helmut Kiene
Journal:  Eur J Health Econ       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.